November, meet us in Berlin and New York

Learn more about our novel target for treatment of chronic inflammatory diseases.
We will attend:
BIO-Europe in Berlin, Nov 6-8
Nordic-American conference in New York, Nov 13-14
RESI meeting in New York, Nov 15

We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected original research data proving the efficacy of the compound in several established arthritis models. The BSSL antibodies effectively block human inflammatory cell migration. We are currently developing a humanized monoclonal antibody that target BSSL and our candidate drug will then be subject for toxicological tests and clinical trials. Lipum is actively seeking partners for a faster development or out-licensing of our technology, read more here

wpadmin2017-11-09T21:19:50+01:00

This website uses cookies and embedded services from third parties. To change the settings and see more detailed information see our Settings Allow all cookies

Third Party Embeds

This website uses cookies and third party services. These features include embedding content such as videos or sharing website content on social media platforms. You can approve by clicking on the content that you allow to be displayed. Then save by clicking Update Settings.

Vimeo
Facebook
Twitter

Tracking Cookies

These cookies store information such as the number of visitors to the website, the number of unique visitors, which pages on the website have been visited, the source of the visit, etc. This data helps us to understand and analyze how well the website works. and where it needs to be improved.

Privacy Policy

From 25 May 2018, the General Data Protection Regulation (GDPR) applies as law in all EU member states.

Read our Privacy Policy

Contact Information

Contact us at info@lipum.se if you have questions about how your personal data is processed by us, or if you wish us to change / delete your personal data.